

Proposed Project Scope

# Enzalutamide for biochemically recurrent nmCSPC prostate cancer

Date: May 2024

## Background and Rationale

CADTH received a request from public drug programs for a Non-Sponsored Reimbursement Review of enzalutamide for biochemically recurrent non-metastatic castration-sensitive prostate cancer.

**Table I: Policy Questions**

Item	Policy Question
1	Should enzalutamide be publicly reimbursed for the treatment of patients with non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk of metastasis (high-risk BCR)?

**Table II: Products Available in Canada**

Product	Manufacturer
Enzalutamide	Astellas Pharma Canada

## Project Description

**Table III: Project Scope**

Criteria	Description
Population	Patients with prostate cancer who have high-risk biochemical recurrence
Intervention(s)	Enzalutamide
Comparators	ADT, abiraterone-prednisone
Outcomes	Overall Survival, Metastasis-free survival, Harms

**Table IV: Research Questions**

Item	Policy Question
1	What is the effectiveness of enzalutamide for the treatment of patients with non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk of metastasis (high-risk BCR)?
2	What are the harms associated with enzalutamide for the treatment of patients with non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk of metastasis (high-risk BCR)?
3	What is the expected cost of enzalutamide for the treatment of patients with non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk of metastasis (high-risk BCR) vs. other reimbursed regimes?

## Key Project and Protocol Components

This project will follow the [Procedures for Non-Sponsored Reimbursement Reviews](#).

## Status of the Document

This proposed project scope is being posted for information.